Zydus Cadila receives USFDA nod for Paroxetine Tablets

New Delhi, Mar 12 (UNI) Cadila Healthcare Ltd today said it has received approval from the US FDA to market Paroxetine Tablets, with an estimated global sales of 850 million dollars.

The drug, an anti-depressant falls in the CNS segment.

The company will market the drug through its subsidiary Zydus Pharmaceuticals (US) Inc.

This marks the 19th ANDA approval for the group since the commencement of filing process in FY 2003-04. So far, the group has filed 46 ANDAs and 46 DMFs.

UNI